Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –
– Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes –
– Favorable safety profile with no treatment-related serious adverse events –